Analysed ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) News Sources
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
12-08-2026
yahoo.com
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
17-04-2026
yahoo.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15-05-2026
yahoo.com
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
21-05-2026
yahoo.com
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
21-07-2026
yahoo.com
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
02-09-2026
yahoo.com
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
03-09-2026
yahoo.com
What is the current price of ACRIVON THERAPEUTICS INC (ACRV:NASDAQ)?
The current price of ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) is $1.64.
ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) since the previous trading day is $-0.12.
ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) since the previous trading day is -6.8182%.
What is the most recent average sentiment score for ACRIVON THERAPEUTICS INC (ACRV:NASDAQ)?
The most recent average sentiment score for ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for ACRIVON THERAPEUTICS INC (ACRV:NASDAQ)?
The most recent sentiment for ACRIVON THERAPEUTICS INC (ACRV:NASDAQ) is .
SEC-8K** Filing Available For ACRIVON THERAPEUTICS INC (ACRV:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.